Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rogletimide

Known as: 3-PYG, 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione, Pyridoglutethimide 
An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Aminoglutethimide
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1996
Highly Cited
1996
Pharmacology of new aromatase inhibitors
Abstract Recent investigations of novel aromatase inhibitors have addressed several important questions related to the… Expand
Highly Cited
1992
Highly Cited
1992
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue Rogletimide (RG) on peripheral… Expand
  • table I
  • figure 2
  • table II
  • table III
  • figure 1
Review
1992
Review
1992
Aromatase Inhibitors: Clinical Pharmacology and Therapeutic Implications in Breast Cancer
  • N. Pérez, J. Borja
  • The Journal of international medical research
  • 1992
    • Corpus ID: 41288672
Aminoglutethimide was the first aromatase inhibitor to be used in breast cancer therapy but, since it interacts with the… Expand
Review
1991
Review
1991
Clinical use of aromatase inhibitors in human breast carcinoma
  • R. Santen
  • The Journal of Steroid Biochemistry and Molecular…
  • 1991
    • Corpus ID: 12629201
The biological importance of aromatase rests in the concept that this is the rate-limiting enzyme involved in estrogen… Expand
1991
1991
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in… Expand
  • table I
  • figure 1
  • table III
  • figure 3
  • figure 2
1991
1991
Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma
Estrone sulfatase is an important mechanism of local synthesis of biologically active estrogens in human breast cancer. The human… Expand
1990
1990
Crystallographic and molecular modeling studies on 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione and its butyl analogue, inhibitors of mammalian aromatase. Comparison with natural substrates: prediction…
Inhibitors of the cytochrome P450 enzyme aromatase, which is involved in the biosynthesis of estrogens from androgens, are of… Expand
1990
1990
Selective aromatase inhibition by pyridoglutethimide, an analogue of aminoglutethimide.
The inhibitory effects of pyridoglutethimide (3-ethyl-3-(4-pyridyl)piperidine-2,6-dione), an analogue of aminoglutethimide, on… Expand
Review
1990
Review
1990
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer
  • M. Dowsett
  • The Journal of Steroid Biochemistry and Molecular…
  • 1990
    • Corpus ID: 10515012
Numerous aromatase inhibitors are under development for breast cancer treatment. The major aims are to obtain a drug which at its… Expand
1987
1987
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione (1) is a strong competitive inhibitor of human placental aromatase (Ki = 1.1 microM… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE